

# **Operating Results & Financial Position, Ended March 2016**

President & CEO Teruhisa Ueda Shimadzu Corporation 2016.5.12

## **Statement of Income**

\* Sales and income increases achieved for a third consecutive year
 \* Record highs achieved for all financials from net sales to profit attributable to owners of parent

\*Operating margin exceeded 10%, and med-term management plan targets for operating margin and operating income achieved a year ahead of schedule


			YoY		
	Mar. 2016	Mar. 2015	Changes	%changes	
Net Sales	342.2	314.7	27.5	8.7%	
<b>Operating Income</b>	35.7	27.2	8.5	31.3%	
<b>Operating Margin</b>	10.4%	8.6%	improvemen	t of 1.8%pt.	
Ordinary Income	34.8	28.4	6.4	22.8%	
Profit attributable to owners of parent	23.9	18.4	5.5	29.6%	
EPS	¥81.05	¥62.55	¥18.50	29.6%	

Billions of Yen, except percentages and EPS

Average Foreign Exchange Rate
 2015.4.1-2016.3.31: \$1 = ¥120.19, €1 = ¥132.63
 2014.4.1-2015.3.31: \$1 = ¥109.98, €1 = ¥138.80

## Analysis of Year-on-Year increase/Decrease in Ordinary Income

- **\*13.4**billion increase in gross profit due to the net sales increase and profitability improvement
- \*1.2point improvement year on year in the ratio of SG&A expenses to sales, despite a ¥4.9billion increase in SG&A expenses
- \* ¥6.4billion increase in ordinary income as a result of ¥2.1billion worsening of non-operating balance because of the impact of yen appreciation and other factors



## **Sales and Income by Business Segment**

- \* Sales increase achieved in each business segment
- \* Driven by Analytical & Measuring Instruments segment, the operating margin in the segment increased to 15.8%
- \* Income improvement and return to profitability in the Aircraft Equipment segment

Billions of yen, except percentages								
Operating Margin i	s listed in right-side column	Mar. 2016		Mar. 2015		Changes %Changes		nges
Analytical &	Net Sales	208.4		192.6		15.8	8.2%	improve
Measuring Instruments	Operating Income	33.0	15.8%	26.8	13.9%	6.2	23.0%	1.9pt.
Medical	Net Sales	64.6	1.6%	59.4	2.4%	5.2	8.7%	deteriorate
Systems	<b>Operating Income</b>	1.0	1.0 /0	1.4	2.470	(0.4)	(27.3)%	0.8pt.
Aircraft	Net Sales	28.8	1.2%	24.8	(9.2)%	4.0	16.1%	improve
Equipment	<b>Operating Income</b>	0.3	1.2 /0	(2.3)	(3.2)70	2.6	—	10.4pt.
Industrial	Net Sales	33.5	6.6%	31.0	6.3%	2.5	8.2%	improve
Machinery	<b>Operating Income</b>	2.2	0.070	2.0	0.570	0.2	12.2%	0.3pt.
Other	Net Sales	6.9	15.4%	6.9	16.0%	0.0	0%	deteriorate
other	<b>Operating Income</b>	1.3	13.470	1.3	10.0%	(0.1)	(3.9)%	0.6pt.
<b>Operating Income Adjustments</b>		(2.1)	—	(2.0)	—	(0.1)	—	
Total	Net Sales	342.2	10.4%	314.7	8.6%	27.5	8.7%	improve
iotai	Operating Income	35.7	10.4%	27.2	0.070	8.5	31.3%	1.8pt.

3

# **Net Sales Breakdown by Region**

- \* Sales increases achieved in all regions
- \* Strong sales in Japan, Europe, and Other Asian countries
- \* Overseas sales ratio of 50.9%, exceeding 50% for the first time

**Sales** YoY Mar. 2016 Mar. 2015 Changes %Changes 167.9 Japan 157.9 10.0 6.4% 8.1% North & South America 46.0 42.6 3.4 > North America 15.1% 41.1 35.7 5.4 26.2 4.2% 27.3 1.1 Europe China 56.1 50.9 5.2 10.3% 25.5 Other Asian countries 32.3 6.8 26.8% 11.6 0.9 7.4% Other 12.5 156.8 11.1% 174.3 17.5 **Overseas** increase by 1.1pt. **Overseas Sales ratio** 50.9% 49.8% Total 8.7% 342.2 314.7 27.5

\* Other Asian countries: Taiwan, Korea, South Asia, and India \* Other: Middle East, Oceania, and Africa

# Analytical & Measuring Instrument Sub-segment Net Sales

- \* Net sales of this business exceeded ¥200 billion, and scale expansion continued
- \* Sales growth from mainstay chromatographs and mass spectrometers drove this business overall
- \* Sales of environmental analyzers and testing machines increased in Asia and Japan, respectively

**Billions** of ven

5


\* Service business sales increased 13% year on year, and the ratio of service sales exceeded

	Billions				
	Sa	les	ΥοΥ		
	Mar. 2016	Mar. 2015	Changes	%Changes	
General Analytical Instruments	136.4	122.9	13.5	11.0%	
>Chromatography(LC,GC&MS)	108.9	97.7	11.2	11.5%	
Surface Analyzers	10.2	10.3	(0.1)	(0.7)%	
Environmental Monitors	11.0	10.5	0.5	4.3%	
Testing Machines & Non-destructive Inspection Machines	20.3	19.4	0.9	5.0%	
Other	30.5	29.5	1.0	3.2%	
Total	208.4	192.6	15.8	8.2%	
> services & parts	57.4	51.0	6.4	12.6%	

# Analytical & Measuring Instruments Net Sales by Region

- **\*** Solid sales in Japan and overseas
- \* Higher private-sector demand in Japan and higher public-sector demand in China and other Asian countries contributed to improved business results
- \* The overseas sales ratio increased by 1.7 points year on year to 58.2%

	Sales		ΥοΥ		
	Mar. 2016	Mar. 2015	Changes	%Changes	
Japan	87.0	83.8	3.2	3.8%	
North & South America	25.5	24.6	1.0	3.9%	
>North America	22.1	20.3	1.8	9.0%	
Europe	22.4	21.4	1.0	5.0%	
China	43.5	37.8	5.7	15.1%	
<b>Other Asian countries</b>	23.2	18.2	5.0	27.6%	
>India	8.5	6.7	1.8	27.7%	
Other	6.7	6.9	(0.2)	(2.9)%	
Overseas	121.4	108.8	12.6	11.6%	
Overseas Sales ratio	58.2%	56.5%	increase by 1.7pt.		
Total	208.4	192.6	15.8	8.2%	



### **Medical Systems Net Sales by Region**

\* Weak sales in China, but solid sales in all other regions

\* Sales in Japan, North America, and other Asian countries drove sales expansion
\* The overseas sales ratio increased by 1.1 points year on year to 48.9%

	Sa	les	ΥοΥ		
	Mar. 2016	Mar. 2015	Changes	%Changes	
Japan	33.0	31.0	2.0	6.3%	
North & South America	10.8	10.1	0.7	7.0%	
> North America	9.3	7.5	1.9	25.2%	
Europe	3.7	3.6	0.1	4.1%	
China	6.1	6.1	0.0	0.4%	
<b>Other Asian countries</b>	5.4	4.0	1.4	36.1%	
Other	5.5	4.6	0.9	19.7%	
Overseas	31.6	28.4	3.2	11.4%	
Overseas Sales ratio	48.9%	47.8%	increase	se by 1.1pt.	
Total	64.6	59.4	5.2	8.7%	

## Aircraft Equipment Sub-segment Net Sales

\* Strong sales in both the defense sector and civil aviation sector
\* Increase in the ratio of sales to the civil aviation sector to 20.7%

	Sa	les	ΥοΥ		
	Mar. 2016	Mar. 2015	Changes	%Changes	
Defence Agency	22.9	20.1	2.8	13.8%	
Passenger Aircraft	6.0	4.7	1.3	25.8%	
Total	28.8	24.8	4.0	16.1%	

#### **Industrial Machinery Sub-segment Net Sales** \* Strong sales of turbo-molecular pumps at a time of active investment in the semiconductor/FPD sector \* Lower sales of hydraulic equipment in China and other markets amid stagnant market conditions, but higher sales in Japan Billions of yen Sales YoY %Changes Mar. 2016 Mar. 2015 Changes Turbo-molecular pumps 10.7 9.6 11.2% 1.1 Hydraulic equipment 11.4 11.4 0.0 0.4% Glass winders etc. 4.9 4.1 0.8 18.8% 6.5 5.9 11.2% Other 0.6 Total 8.2% 33.5 31.0 2.5

**SHIMADZU** 

## **Industrial Machinery Net Sales by Region**

\* Sales expansion in Japan drove overall growth

\* Solid sales of turbo-molecular pumps for the semiconductor industry in North America, but unfavorable sales of turbo-molecular pumps and hydraulic equipment for glass coating in China

	Sal	es	ΥοΥ		
	Mar. 2016	Mar. 2015	Changes	%Changes	
Japan	18.2	16.0	2.1	13.3%	
North & South America	4.2	3.5	0.7	21.2%	
>North America	4.1	3.5	0.7	19.3%	
Europe	0.8	1.0	(0.3)	(27.0)%	
China	6.5	7.0	(0.5)	(7.2)%	
Other Asian countries	3.6	3.3	0.3	9.8%	
Other	0.3	0.1	0.1	×2.2	
Overseas	15.3	14.9	0.4	2.8%	
<b>Overseas Sales ratio</b>	45.8%	48.2%	desrease	by 2.4pt.	
Total	33.5	31.0	2.5	8.2%	

## **Balance Sheet**

- \* Total assets increased by ¥10.0 billion
- \* Although total liabilities remained at the level of the previous fiscal year-end, interest-bearing liabilities decreased.
- \* Equity capital increased, and the equity ratio increased by 1.1 points from the previous fiscal year-end to 62.8%.

Billions of yen, except percentages

	Ass	sets	Y	σY		Liabi	lities	Yo	ρΥ
	2016.3.31	2015.3.31	Changes	%Changes		2016.3.31	2015.3.31	Changes	%Changes
Current assets	241.7	234.8	6.9	2.9%	Current libilities	97.6	100.6	(3.0)	(3.0)%
Inventories	73.7	74.9	(1.2)	(1.6)%	Long-term liabilities	32.2	29.2	3.0	30.7%
Noncurrent assets	108.1	105.0	3.1	3.0%	interest-bearing liabilities	19.2	24.7	(5.5)	(22.4)%
Total assets	349.8	339.8	10.0	2.9%	Total liabilities	129.8	129.8	0.0	0.0%

	Net a	issets	YoY		
	2016.3.31	2015.3.31	Changes	%Changes	
Equity capital	219.7	209.8	9.9	4.7%	
Non- controlling interests	0.3	0.2	0.1	11.7%	
Total liabilities and net assets	349.8	339.8	10.0	2.9%	
Equity ratio	62.8%	61.7%	increase by 1.1pt.		

## **Statement of Cash Flows**

- \* Free cash flow was a positive ¥19.2billion, and financial cash flow was a negative ¥11.7 billion due to repayments of long-term debt and short-term loans, among other factors
- \* Cash and cash equivalents at the fiscal year-end increased by ¥5.1billion from the previous fiscal year-end to ¥43.5billion

			Billions of yen
	Mar. 2016	Mar. 2015	Changes
CF-Operating activities	32.3	40.2	(7.9)
CF-Investing activities	(13.1)	(15.7)	2.6
Free Cash Flows	19.2	24.6	(5.4)
<b>CF-Financial activities</b>	(11.7)	(33.2)	21.5
Foreign currency translation adjustments			
on cash and cash equivalents	(2.5)	2.4	(4.9)
Net increase (decrease) in cash and cash			
equivalents	5.1	(6.2)	11.3
Cash and cash equivalents, beginning of			
period	38.4	43.9	(5.5)
Cash and cash equivalents, end of period	43.5	38.4	5.1

13

# **Business Environment Outlook**

	Modest upward trend in corporate capital investment
Japan	<ul> <li>(Risks) Decline in corporate investment sentiment due to a downturn in overseas market conditions and yen appreciation</li> </ul>
United States	Continuation of investment in the healthcare, biotech and other leading-edge sectors in a robust economy (Risks) Decline in corporate investment sentiment due to sluggishness in the manufacturing industry
Europe	Investment in private-sector demand sectors such as pharmaceuticals, food safety, and chemicals (Risks) Impact on business conditions of the after-effects of economic stagnation in China and geopolitical factors originating in the Middle East
China	Demand increases in areas such as pharmaceuticals, food safety, environmental conservation in the 13th Five Year Plan, and R&D investment in leading-edge sectors (Risks) Prolonged adjustment of excess facilities, a further downturn in business conditions, etc.
Asia	Stable expansion resulting from expansion of the Indian economy, launch of the Asean Economic Community (AEC) and middle class expansion in the ASEAN region (Risks) After-effects of economic stagnation in China, effects of currency weakness, etc.

## **Earnings Forecast**

\* Plan for sales and income increases from new product introductions, strengthening of the aftermarket business, and other factors
\* Aim to achieve the medium-term management plan target operating margin of 10% or higher through high-end product expansion and cost reductions

			Yo	Y	
	Mar. 2017 Forecast	Mar. 2016	Changes	%Changes	
Net Sales	350.0	342.2	7.8	2.3%	
Operating Income	36.0	35.7	0.3	0.8%	
Operating Margin	10.3%	10.4%	deterioration of 0.1%pt.		
Ordinary Income	34.5	34.8	(0.3)	(1.0)%	
Profit attributable to owners of parent	24.0	23.9	0.1	0.4%	
EPS	¥81.40	¥81.05	¥0.35	0.4%	
Average foreign exc	hange rate				

: \$1 = ¥ 120.19, €1 = ¥ 132.63

2016.4.1-2017.3.31 forecast : \$1 = ¥ 110.00, €1 = ¥ 125.00

2015.4.1-2016.3.31

Billions of yen, except percentages

## **Earnings Forecast by Business Segment**

 \* Aim to establish an earnings base of an operating margin of 10% or higher
 \* Plan for sustained growth in the Analytical & Measuring Instruments and Medical Systems segments
 \* Strive for profitability improvement in the Medical Systems segment and


\* Strive for profitability improvement in the Medical Systems segment and earnings stabilization in the Aircraft Equipment segment

					ΥοΥ			
Operating Margin is listed in right-side column		Mar. 2017Forecast		Mar. 2016		Changes	%Changes	
Analytical & Measuring	Net Sales	218.0	15.4%	208.4	15.8%	9.6	4.6%	deteriorate
Instruments	Operating Income	33.5	13.470	33.0	15.8%	0.5	1.6%	0.4pt.
Medical	Net Sales	66.5	3.8%	64.6	1.6%	1.9	3.0%	- · -
Systems	Operating Income	2.5	5.070	1.0		1.5	×2.4	
Aircraft	Net Sales	26.0	1.2%	28.8	1.2%	(2.8)	(9.9)%	unchange
Equipment	Operating Income	0.3		0.3		0.0		
Industrial	Net Sales	33.0	5.5%	33.5	6.6%	(0.5)	(1.5)%	deteriorate
Machinery	Operating Income	1.8	5.570	2.2		(0.4)	(18.4)%	1.1pt.
Other	Net Sales	6.5	12.3%	6.9	15.4%	(0.4)	(5.0)%	deteriorate
	Operating Income	0.8		1.3		(0.5)	(36.8)%	3.1pt.
<b>Operating Income Adjustments</b>		(2.9)	—	(2.1)	—	(0.8)	—	
Total	Net Sales	350.0	10.3%	342.2	10.4%	7.8	2.3%	deteriorate
	Operating Income	36.0		35.7		0.3	0.8%	0.1pt.

#### 🕀 SHIMADZU

## **Cash Dividend and Payout Ratio**

 Continue paying stable cash dividends
 Plan to pay an annual dividend of ¥20 per share for the fiscal year ending March 31, 2017, an increase of ¥2 from the previous fiscal year (Planned payout ratio of 24.6%)





# Progress against the Medium-Term Management Plan – Contents –

1. Performance Targets p.19					
2. Growth Strategy p.20					
I Activate markets with products resulted from					
advanced technology and latent needs p.20					
Mass Spectrometers, Liquid Chromatographs, Medical Systems					
I Develop business in new fields through joint research					
with advanced customers p.23					
Build a business foundation that ensures acquiring growth potential					
in newly emerging economiesp.24					
<b>IV</b> Provide services optimized for customers based on					
analyzing product life cycles p.25					
3. Principle Measures in FY 2016 to Achieve Targets					


.....p.26



# Progress against the Medium-Term Management Plan (1) — Performance Targets

\*Solid results in Years 1 and 2 and a strong push to complete the plan in Year 3 \*Approach the net sales target for FY2016; operating income target exceeded a year ahead of schedule

\*Progress with profitability improvement, mainly in the Measuring Instruments segment, by means including expansion of the line of global strategic products





## Progress against the Medium-Term Management Plan (2) – Growth Strategy I / Mass Spectrometers

- \*Sequential introduction of four TQ-LCMS models since 2010 to expand and upgrade the product line, from a basic model to a high-end model
  \*Steadily increasing sales of mass spectrometers, with sales approaching the management plan FY2015 target of ¥33.2 billion
  \*ICPMS newly introduced in March 2016 with the aim of achieving sustained sales growth
- from mass spectrometers

### LCMS

Ultra-high sensitivity and high-speed performance open up new fields, such as pain management and clinical applications



### ICPMS

Highly sensitive trace element analysis, realization of low running cost through reduction of the amount of argon gas used

Analysis of water quality, analysis of elemental impurities in pharmaceutical products, analysis of organic micro-contaminants in food products



#### GCMS

Expansion of application fields to healthcare and newly regulated substances in addition to food, environment, chemicals, and forensic medicine

Colon cancer diagnosis, dioxin analysis, analysis of substances controlled under RoHS directive and REACH regulations



#### MALDIMS

Expansion of applications to include microorganism identification
 The MALDI-7090, which is high the popular at universities and other research organizations, realizes unparalleled resolution



# **Progress against the Medium-Term Management**

#### TOPICS

Plan (3) – Growth Strategy I / Liquid Chromatographs

\*Global expansion of the i-Series line of integrated high-speed liquid chromatographs, which offer ease of use and enhanced operating efficiency \*Strong sales performance of the Nexera UC supercritical liquid chromatograph system,

- which realizes fully automated, high-speed analysis with no troublesome preprocessing for such as residual agricultural chemicals
- \*Liquid chromatograph net sales exceeded the FY2015 management plan target of ¥54.0 billion a year ahead of schedule

#### **i-Series**

 Integrated high-speed liquid chromatographs that offer ease of use and enhanced operating efficiency
 Also used as dedicated analyzers

#### Nexera X2

Ultra-high-speed liquid chromatographs that offer superior speed, sensitivity, resolution, and stability

A valuable resource in wide-ranging fields including medicine, biochemistry, chemicals, environment, and food products



### Nexera UC

General-purpose high-speed chromatographs that offer high reliability and extensibility

**Prominence** 

A valuable resource in wide-ranging fields including medicine, biochemistry, chemicals, the environment, and food products

Global expansion underway, mainly overseas

in India, the U.S., and Europe



Supercritical liquid chromatograph system, which realizes fully automated, high-speed analysis with no troublesome preprocessing

Contributes to throughput improvement in the pharmaceuticals, food products,



chemicals, environment, and forensic medicine fields

# **Progress against the Medium-Term Management**

**Plan (4)** – Growth Strategy I / Medical Systems

 \*Acceleration of globalization of the strategic products X-ray fluoroscopy systems and angiography systems
 \*Introduction of PET mammography systems and near-infrared imaging systems, strengthening of business development in the field of therapy

### X-ray Fluoroscopy Systems

Installation of applications that support wideranging diagnostic department needs, improvement of diagnostic efficiency through multi-purpose examination support

A single system that makes possible gastrointestinal, orthopedics, and urology examinations with wideranging applications such as bone densitometry, 140 cm transversal coverage, tomography, and a movable bed



### "Only One" Product

Provision of a new approach to breast cancer diagnosis and treatment support





### **Angiography Systems**

Minimally invasive (low exposure, less contrast medium, shorter treatment times), high image quality through image processing, global availability of the latest clinical applications



### New Business: Intraoperative Assistance System

# ■ Intraoperative assistance from a new imaging system that uses near-infrared fluorescence

Visualization of blood vessels and lymphatic vessels using a fluorescence agent, improvement in surgical efficiency





Establishment of a platform for metabolome analysis

# Progress against the Medium-Term Management Plan (5) – Growth Strategy II


"Develop new fields through expansion of joint research with advanced customers." Accelerate the development of advanced applications and their deployment in new fields by promoting joint research with advanced customers.


United States	China				
Clinical / Medicine / Environment	Food products / Environment / Clinical Chinese Academy of Sciences, Peking University, Tsinghua University, Tianjin University of Traditional Chinese Medicine				
Johns Hopkins University Development of a test kit in preparation for tightening of FDA regulations	Development of dynamic observation applications for medicines, metabolites, lipids, etc.				
Europe	Asia				
<ul> <li>Food products / Composites / Imaging / Clinical</li> <li>University of Messina (Italy) Development of an analysis system for functional ingredients in food</li> </ul>	<ul> <li>Environment / Food safety / /Healthcare</li> <li>National University of Singapore</li> <li>Leading-edge development in the clinical application and food safety fields (under discussion)</li> </ul>				
Japan					
Food products / Life sciences / Clinical / Medicine					
Osaka University joint research chair					



# Progress against the Medium-Term Management Plan (6) – Growth Strategy III

### "Build a business foundation that ensures growth in emerging markets." Implementation of an Asian market strategy.





### Strengthening of product development capabilities

- \*Local development at the development center in China \*Joint research with advanced universities in Southeast Asia
- Strengthening of the applications development function
  - \*Mass spectrometry center in Beijing, China (Oct. 2015)

### Strengthening of networking support

\*Asia innovation center (planned for autumn 2016)

### Expansion of the production function

- \*New factory in Malaysia (planned start of shipments in Sept. 2016)
- \*Expanded production of products developed in China at the Suzhou factory






# Progress against the Medium-Term Management Plan (7) – Growth Strategy IV

### "Provide service optimized for customers focused on product life cycles." Bolster the aftermarket business.

#### **Aftermarket Business Net Sales**



#### Measuring Instruments

\*Strengthening of product remote capabilities (M2M promotion for Measuring Instruments)
\*Strengthening of multi-vendor services
\*Enhancement of the line of own-brand consumables

#### Medical Systems

\*Expansion of the service business in the U.S., China, and Asia

\*Development of a rapid parts supply system

#### Industrial Machinery

\*Setting up turbo-molecular pump service sites worldwide and expansion of the aftermarket business TOPICS

# **Progress against the Medium-Term Management**

Plan (8) – Principle Measures in FY 2016 to Achieve Targets

#### **New Products**

Measuring Instruments: Enhancement of product lines that reflect global needs in the pharmaceuticals, chemicals, food products, environment, and healthcare sectors

■ Industrial Machinery: Enhancement of ball bearingtype products, supply of turbo-molecular pumps in more wide-ranging fields

#### **Software and Applications**

Measuring Instruments: Promotion of development of software and applications adapted to regulations and needs in areas around the world centered on innovation centers in the U.S., China, Europe, and Asia

Medical Systems: Enhancement of clinical applications such as multi-purpose examination and surgical assistance

#### Aftermarket

Measuring Instruments: Offering of new services utilizing M2M worldwide

■ Aircraft Equipment: Strengthening of the aftermarket business in the civil aviation sector

■ Industrial Machinery: Expansion of the turbomolecular pumps aftermarket business

#### **New Businesses**

Measuring Instruments: Promotion of the molecular diagnostics business (colon cancer examination system, rapid pathological diagnosis support system, etc.) and cell analysis business

Medical Systems: Introduction of near-infrared fluorescence imaging systems for intraoperative assistance, reinforcement of business development in the diagnostics field



This document contains forward-looking statements. Forecasts of future business performance that appear in this document are predictions made by the Company's management team and are based on information available when these materials were prepared; they are subject to risks and uncertainties. For this reason, actual results may differ materially from the forecasts made here. Factors that may influence actual business performance include, but are not limited to, economic conditions in Japan and abroad, changes in technologies in markets, and fluctuations in exchange rates. The Company does not undertake to update its forward-looking statements.